What is the level of liabilities of Inhibrx this year?
Inhibrx has a debt balance of 264.39 M USD this year.
Inhibrx Liabilities 2024
Inhibrx Liabilities
264.39 M USD
Ticker
INBX
ISIN
US45720L1070
WKN
A2PQMH
In 2024, Inhibrx's total liabilities amounted to 264.39 M USD, a 13.57% difference from the 232.8 M USD total liabilities in the previous year.
Inhibrx Aktienanalyse
What does Inhibrx do?
Inhibrx Inc is a biopharmaceutical company specializing in the development and commercialization of therapeutic antibodies. The company was founded in 2011 and is headquartered in La Jolla, California. Inhibrx's business model is based on the research and development of innovative antibodies targeting various diseases such as cancer, inflammation, autoimmune diseases, and infectious diseases. The company utilizes proprietary technologies and platforms to produce a wide range of antibodies that specifically target and block key proteins in the body. Inhibrx is divided into two business segments: the clinical development department and the research and development department. The clinical development department is responsible for conducting clinical trials of the company's antibodies. The research and development department is responsible for the development and refinement of new antibody platforms and technologies. Inhibrx has a number of products in the pipeline, including IRX-2, an antibody developed for the treatment of patients with solid tumor diseases. IRX-2 targets the PD-L1 and PD-L2 proteins, which are overexpressed by many cancer cells and help tumor cells evade immune defenses. In clinical studies, IRX-2 has shown significant reduction in tumor volume in many patients. Another promising product from Inhibrx is IRX-6, an antibody developed for the treatment of autoimmune diseases such as lupus and rheumatoid arthritis. IRX-6 targets the protein BAFF, which plays a key role in the activation of immune cells. Inhibrx has also partnered with pharmaceutical company Celgene Corporation to develop new cancer therapies. As part of the partnership, Inhibrx will utilize its proprietary antibody platforms and technologies to identify and develop new cancer therapies. Inhibrx has an excellent reputation in the industry and has been recognized multiple times for its innovative approaches and technologies. The company has secured a place among the leading biopharmaceutical companies and is expected to continue playing a significant role in the development of new therapies. Inhibrx ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Inhibrx's Liabilities
Inhibrx's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Inhibrx's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Inhibrx's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Inhibrx's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Inhibrx’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Inhibrx stock
What were the liabilities of Inhibrx compared to the previous year?
The liabilities of Inhibrx have increased by 13.57% increased compared to the previous year.
What are the consequences of high debt for investors of Inhibrx?
High liabilities can pose a risk for investors of Inhibrx, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Inhibrx?
Low liabilities mean that Inhibrx has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Inhibrx affect the company?
An increase in liabilities of Inhibrx can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Inhibrx affect the company?
A decrease in the liabilities of Inhibrx can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Inhibrx?
Some factors that can influence the liabilities of Inhibrx include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Inhibrx so important for investors?
The liabilities of Inhibrx are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Inhibrx take to modify the liabilities?
To change its liabilities, Inhibrx can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Inhibrx pay?
Over the past 12 months, Inhibrx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibrx is expected to pay a dividend of 0 USD.
What is the dividend yield of Inhibrx?
The current dividend yield of Inhibrx is .
When does Inhibrx pay dividends?
Inhibrx pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Inhibrx?
Inhibrx paid dividends every year for the past 0 years.
What is the dividend of Inhibrx?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Inhibrx located?
Inhibrx is assigned to the 'Health' sector.
Wann musste ich die Aktien von Inhibrx kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Inhibrx from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.
When did Inhibrx pay the last dividend?
The last dividend was paid out on 11/8/2024.
What was the dividend of Inhibrx in the year 2023?
In the year 2023, Inhibrx distributed 0 USD as dividends.
In which currency does Inhibrx pay out the dividend?
The dividends of Inhibrx are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Inhibrx
Our stock analysis for Inhibrx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibrx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
